MYLAN PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS INDUSTRIES LTD. et al

A federal court issued an order in Mylan Pharmaceuticals Inc. v. Teva Pharmaceuticals Industries Ltd.

et al (D.N.J., No. 2:21-cv-13087) on April 20, 2026, alongside a docket entry with no description — leaving the substance of both filings unclear.

Mylan filed this case in 2021 in the District of New Jersey, the default venue for Hatch-Waxman patent fights. Under that framework, a brand or generic manufacturer can sue a competitor who files an Abbreviated New Drug Application (ANDA) certifying that a listed patent is invalid or not infringed.

Filing suit triggers an automatic 30-month stay on Food and Drug Administration (FDA) approval of the generic, making the litigation directly tied to when a competing drug can reach the market.

The core disputes here track the standard Hatch-Waxman playbook: patent validity, infringement scope, and who gets market exclusivity and for how long. What makes this case unusual is the plaintiff.

Mylan is itself a major generic manufacturer — now operating as Viatris after a 2020 merger — which means this is a generic-versus-generic fight over patent rights, not a brand company defending against a generic challenger. Teva is the other dominant player in the U.S. generic drug market.

The stakes are commercial, not just legal: whichever side controls the relevant patents controls the timing of generic entry.

The case has been active for nearly five years. That span typically means the parties have completed claim construction, exchanged expert reports, and are either in late-stage summary judgment briefing or approaching trial. The April 20 order could reflect a scheduling change, a discovery ruling, or a dispositive motion decision — the blank docket entry makes it impossible to say which.

The identity of the additional defendants and the specific drug products at issue are not confirmed in the available record. Both gaps matter. Additional defendants often hold licenses or have their own ANDA filings that affect the infringement analysis.

The drug product determines which patents are in play and what the commercial upside looks like for each side.